Healthcare
Live Price
Offline$63.16
+0.98% today
1Y Change
+55.57%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 250 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Tarsus Pharmaceuticals, Inc. (TARS) is a Healthcare stock with a market cap of $2.71B and listed on NASDAQ. The stock last traded around $63.16 and up 55.6% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of +146.7%, EPS growth of +48.2%, a dividend yield of 0.0%. What stands out right now is revenue +146.7%, EPS +48.2%, free cash flow +73.6% with operating margin -15.7% and ROIC -16.6%. Valuation sits in the middle of the pack at price/sales 6.0. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines TARS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TARS
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TARS Max Drawdown
-30.42%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TARS and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$57.0M
+120.9% YoY
FY Net Income
-$13.8M
+77.7% YoY
Free Cash Flow
$3.2M
+106.4% YoY
Revenue Growth
+146.7%
EPS Growth
+48.2%
Gross Margin
89.6%
Net Margin
-14.7%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 451M | 183M | 17M | 26M | 57M |
| Gross Profit | 421M | 170M | 16M | 25M | 55M |
| Operating Income | -71M | -121M | -143M | -63M | -12M |
| EBITDA | -54M | -106M | -132M | -60M | -13M |
| Net Income | -66M | -116M | -136M | -62M | -14M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 184M | 95M | 225M | 72M | 171M |
| Total Assets | 562M | 377M | 265M | 228M | 179M |
| Total Liabilities | 219M | 152M | 69M | 35M | 12M |
| Shareholder Equity | 343M | 225M | 197M | 193M | 167M |
| Total Debt | 94M | 72M | 30M | 20M | 2M |
| Net Debt | -90M | -22M | -195M | -51M | -169M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
4M
+107.6% YoY
Capital Expenditures
586K
-15.8% YoY
Free Cash Flow
3M
+106.4% YoY
Key ratios
Gross Margin
89.6%
Operating Margin
-15.7%
Net Margin
-14.7%
ROE
-19.6%
Debt / Equity
0.27x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.